Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Cosmo Pharma Rises on Bowel Disease Drug Approval: Zurich Mover

Cosmo Pharmaceuticals SpA, an Italian developer of a drug for a type of bowel disease, rose to a record after its U.S. partner Santarus Inc. won regulatory approval for the treatment.

Cosmo climbed 8.1 percent to 37.25 Swiss francs in Zurich, giving the company a market value of 559 Swiss francs ($602 million). Today’s advance was the biggest in over six months, and the stock reached the highest price since the company went public in March 2007. Volume was more than six times the daily average for the past three months.

Santarus won Food and Drug Administration approval to market the drug, Uceris, as a treatment for patients with active, mild to moderate ulcerative colitis, Lainate, Italy-based Cosmo said in a statement today.

Uceris may generate sales of as much as $190 million, according to Peter Welford, an analyst at Jefferies International Ltd. in London.

The disease, which afflicts as many as 700,000 people in the U.S., produces ulcers in the colon that can cause cramping, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.